Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial - Dearnaley, D; Syndikus, I; Mossop, H; Khoo, V; Birtle, A; Bloomfield, D (Lancet Oncol, 2016)